Zura Bio discontinues tibulizumab in HS after Phase II trial failure

PepGen (PEPG) surged 114% after positive Phase 2 data for its muscular dystrophy treatment. Zura Bio (ZURA) rose 15% despite discontinuing a clinical program. NeOnc (NTHI) gained 13% following CEO share purchases. Senseonics (SENS) advanced 12% after raising its revenue outlook on strong Q3 growth.

Guggenheim reduced its price target for Zura Bio (ZURA) to $8 from $20 after its Phase II trial for hidradenitis suppurativa failed. The stock is at $1.19, down 18.5% YTD. ZURA will discontinue Tibulizumab development for this indication but focus on systemic sclerosis, with data expected in 2027. The company has negative cash flow but strong liquidity.

Zura Bio (ZURA) halted development of tibulizumab for hidradenitis suppurativa after its Phase 2 trial failed to meet primary and key secondary goals. Both doses showed similar reductions in abscesses and inflammatory nodules compared to placebo. The company will continue developing the drug for systemic sclerosis and polymyalgia rheumatica. ZURA had $187.7M in cash as of September 30, 2026, and its stock is down 72.24% to $1.13.

Zura Bio (ZURA) halted development of tibulizumab for hidradenitis suppurativa after its Phase 2 trial missed primary and key secondary endpoints. The study showed limited differences versus placebo. Zura will continue evaluating tibulizumab in other conditions and has $187.7M in cash to fund operations through 2028.

Zura Bio's stock fell 68.2% after its Phase 2 trial for tibulizumab in hidradenitis suppurativa failed to meet primary and secondary endpoints. The company halted development for this indication, leaving two other trials in its pipeline. Zura Bio has $187.7M in cash, expected to last until 2028, but the market reacted negatively to the setback.

Zura Bio's experimental drug, tibulizumab, failed to meet the main goal of a mid-stage trial for treating hidradenitis suppurativa, a chronic skin disease. The drug also missed key secondary goals. The company's shares fell over 70% in premarket trading. Zura plans to discontinue development for this indication but will continue studying the drug for other conditions. The company reported $187.7 million in cash reserves as of September 30.